You are here

Valeant's mistakes raised profit, destroyed value: Ackman

Pharma company raised drug prices sky-high after strategic acquisitions

Mr Pearson told the Congressional committee that "Valeant was too aggressive. And I, as a leader, was too aggressive."


AFTER US$77 billion in lost market value, congressional hearings and corporate stumbles, Valeant Pharmaceuticals International Inc's CEO and its biggest hedge fund booster stood before a Senate committee, raised their right hands in truth, and said the drug company had gotten

Market voices on:

Powered by GET.comGetCom